Potential leptin therapy for nonalcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z × Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member Potential leptin therapy for nonalcoholic steatohepatitis Download PDF Copy Reviewed Reviewed by Emily Henderson, B.Sc. Jun 7 2021 In those with fatty liver disease, a person's fat goes to their liver instead of their fat tissue, either because of an absence of fat depots, which is seen in the rare genetic disease lipodystrophy, or because the depots are too full, which is seen in people with obesity. One third of these people will go on to develop nonalcoholic steatohepatitis, or NASH - an advanced form of fatty liver disease brought on by progressive inflammation and scarring in the organ. In 2002, Michigan Medicine endocrinologist Elif Oral, M.D., who had just moved from the National Institutes of Health at the time, published her discovery that patients with severe lipodystrophy lack leptin, a hormone that helps curb appetite and control weight gain. When given leptin as a supplement, the patient's serious metabolic abnormalities like NASH improved substantially. Oral set out to U-M to further study the role of leptin, now in more common forms of NASH. Almost two decades later, her research team found that whether from a leptin deficiency or the presence of partial lipodystrophy, patients with NASH and relatively low leptin levels can mobilize the extra fat in their liver, out of their liver, and help reverse their condition by undergoing leptin therapy. Familial partial lipodystrophy often accompanies NASH. It's a rare, genetic condition where patients have a lack of fat in their extremities but remain fat in their upper body. I wanted to test the effect of leptin in both those with this rare condition and those that just present with NASH to see if there would be a difference in therapeutic outcomes." Elif Oral, M.D., Michigan Medicine Endocrinologist This work, which is the first of its kind in humans and compiles research from three different studies, showed that leptin is an important signal in regulating fat deposition in the liver, and reversing fat deposition and its subsequent NASH. During the lifetime of the study, the manufacturer of leptin changed several times, posing substantial bureaucratic obstacles for the research team to overcome. "I could've moved on to something easier to study, but I wanted to see this through. This is my life's work," Oral said. "I'm grateful for all of my collaborators and co-authors for sticking with me through it all." Related Stories Cornell study finds existing drug could boost liver cancer immunotherapy Short-duration psychedelic therapy shows promise for major depression treatment Engineered liver tissue model mimics early metabolic liver disease Outlined in Med: Cell Press , Oral and her team conducted two open-label trials studying nine male patients with NASH and relatively low leptin levels (less than 9 ng/ml) and 23 patients with both partial lipodystrophy and NASH. Both groups received leptin therapy in the form of metreleptin for one year. The trials consisted of male patients because Oral found that 35-40% of the men that had leptin levels measured had levels less than the twenty-fifth percentile of their body weight, making them ideal study candidates. "Not all NASH is created equal. There's a vast distribution of leptin levels in this patient population," Oral said. "High levels of leptin, seen in obesity, can actually be causative of NASH so it was important to carefully select trial participants for low levels." After blind, paired liver biopsies, both groups were found to have reduced fat in the liver and lower NASH scores after 12 months of leptin therapy. The patients also had improved insulin sensitivity and body weight. The findings are only applicable to leptin, but Oral thinks other molecules or treatments that activate leptin in the body could be of focus in future studies in an attempt to widen the therapeutic window for these patients. After obesity is established, there's little gain by giving someone leptin. However, a patient in the early overweight state may get value from undergoing leptin therapy, inspiring the research team to study leptin as a preventive weight control option in those at risk of crossing the obesity threshold and developing more fat in the liver. "Although these results were encouraging, this justifies a larger trial," Oral said. "But there's no approved treatments for NASH of any form, so to have a therapeutic that can help at least a fraction of these patients is exciting." Source: Michigan Medicine - University of Michigan Journal reference: Akinci, B., et al. (2021) Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. Med: Cell Press. doi.org/10.1016/j.medj.2021.04.001 . Posted in: Medical Science News | Medical Research News | Medical Condition News Comments (0) Download PDF Copy Suggested Reading Not all children with autism benefit from early language therapy Researchers develop new score to predict the risk of liver cancer Diagnostic prognostic and therapeutic relevance of PIVKA-II in hepatocellular carcinoma Bacterial infections in patients with liver cirrhosis show rising prevalence and high mortality Liver-derived protein supports bone health in males MET signaling plays a critical protective role in acetaminophen-induced acute liver failure SynGenSys introduces Liver.SET synthetic promoter library for liver-specific gene expression for in vivo gene therapies Study explores whether a bidirectional causal link exists between MASLD and sarcopenia Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Sign in to keep reading We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free. Sign in with Google Sign in with Apple Sign in with LinkedIn Sign in with Facebook or Sign in with email Trending Stories Latest Interviews Top Health Articles Case report examines potential cancer risks after mRNA vaccination Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation Researchers identify a previously unknown cellular barrier in the brain Ozempic users continue treatment when weight loss works despite side effects Advancing brain microphysiological systems (bMPS) Dr. Lena Smirnova Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. PhD researcher at LifeArc Natasha Bury Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research Rosanna Zhang In our latest interview, News-Medical speaks with Rosanna Zhang from ACROBiosystems about utilizing organoids for disease modeling in the field of neuroscience research. Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Camel Milk Nutrition Facts and Potential Health Benefits Explained Edible Insects as Food: Nutritional Benefits, Safety, and Environmental Impact Latest News Novel implant delivers tiny growth-promoting particles directly to injured nerve cells Changes in lymphatic vessels can help identify aggressive oral cancer at an early stage Axol Bioscience acquires ophthalmology business from Newcells Biotech Researchers find new way to halt leukemia stem cell growth Study examines the effectiveness of urine testing as a screening tool for alcohol use in pregnancy Newsletters you may be interested in Genetics ( Subscribe or Preview ) Diabetes ( Subscribe or Preview ) Endocrinology ( Subscribe or Preview ) See all Newsletters » High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home Functional Food News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Posters Podcasts Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Posters Podcasts Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions . Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Wednesday 18 Feb 2026 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2026 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content . Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI . Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy . Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms . Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Do cocoa flavanols influence heart and fatty liver risk factors?